Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q1 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals significant financial challenges, including a net loss increase and zero revenue for Q1 2025, raising concerns about financial sustainability. Despite a strong cash position and potential milestone payments, extended negotiations and increased expenses further contribute to a negative outlook. The Q&A session highlighted uncertainties in regulatory progress and market entry delays. Overall, the financial struggles and uncertainties outweigh the potential positive impacts, leading to a negative sentiment rating.
Key Financial Performance
EPS $-0.53 EPS, a decrease from $-0.33 EPS year-over-year.
Cash Position Approximately $144.8 million as of March 31, 2025, compared to $145 million in the previous period.
Revenue $0 for Q1 2025, a decrease of approximately $4.9 million from Q1 2024, due to the full recognition of a $40 million distribution agreement with Nippon Shinyaku in 2024.
R&D Expenses Approximately $16.2 million in Q1 2025, an increase from approximately $10.1 million in Q1 2024.
G&A Expenses Approximately $3.1 million in Q1 2025, an increase from approximately $1.8 million in Q1 2024.
Net Loss Approximately $24.4 million in Q1 2025, compared to a net loss of approximately $9.8 million in Q1 2024.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Product Approval Progress: Capricor is seeking full approval for deramiocel to treat Duchenne muscular dystrophy (DMD) cardiomyopathy, with a smooth path to FDA and a positive outlook on the BLA application.
Clinical Data Support: The BLA filing is based on the HOPE-2 study and its open-label extension, showing statistically significant differences in heart function.
New Chief Medical Officer: Dr. Michael Binks has been appointed as the new Chief Medical Officer, bringing over 25 years of experience in clinical development.
Market Expansion: Capricor is negotiating with Nippon Shinyaku for the distribution of deramiocel in Europe, with an extended negotiation period until the end of Q2 2025.
International Expansion Plans: Plans to expand the HOPE-3 trial internationally are being evaluated.
Manufacturing Capabilities: The San Diego GMP manufacturing facility is operational and producing doses of deramiocel, with an expansion planned for mid to late 2026.
Strategic Shift to Commercial Stage: Capricor is transitioning from a translational medicine company to a commercial stage entity, focusing on launch readiness for deramiocel.
Vaccine Development: The company is advancing its vaccine program under Project NextGen, with Phase 1 trials set to start in Q3 2025.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Earnings Expectations: Capricor Therapeutics missed earnings expectations with a reported EPS of $-0.53, compared to the expected $-0.33.
Regulatory Risks: Concerns were expressed regarding the FDA advisory committee meeting for Capricor, although the company views this as a positive opportunity to showcase their data.
Market Competition: Deramiocel is not designed to compete with existing therapies for dystrophinopathy, which may limit its market potential.
Supply Chain Challenges: The company is expanding its manufacturing capabilities to meet potential demand, indicating a proactive approach to supply chain management.
Financial Position: The company reported a net loss of approximately $24.4 million for Q1 2025, compared to $9.8 million in Q1 2024, raising concerns about financial sustainability.
Revenue Generation: Revenues for Q1 2025 were zero, a significant drop from $4.9 million in Q1 2024, indicating challenges in revenue generation.
Cash Runway: Capricor has a cash balance of approximately $145 million, which is projected to last until 2027 without additional cash infusions.
Partnership Risks: Negotiations with Nippon Shinyaku for European distribution have been extended, indicating potential delays in market entry.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
BLA Progress: Capricor is seeking full approval for deramiocel in treating Duchenne muscular dystrophy cardiomyopathy, with a smooth path to FDA approval expected.
FDA Advisory Committee Meeting: Participation in an FDA advisory committee meeting is viewed positively, allowing Capricor to showcase strong scientific and clinical data.
Commercial Transition: Plans to transition over 100 patients from clinical to commercial product following potential BLA approval.
Manufacturing Expansion: Expansion of the San Diego GMP manufacturing facility is underway, expected to be operational mid to late 2026.
European Partnering Opportunities: Negotiations with Nippon Shinyaku for potential distribution of deramiocel in Europe are ongoing, with an extension of the negotiation period.
Exosome Program Development: Continued development of the stealth exosome platform technology as a next-generation drug delivery platform.
COVID-19 Vaccine Development: Phase 1 of the COVID-19 vaccine trial is set to start in Q3, with collaboration with NIAID.
Cash Position: Cash balance totals approximately $145 million, with a runway into 2027 without additional cash infusions.
Potential Milestone Payments: If FDA approval is received, Capricor expects an $80 million milestone payment from Nippon Shinyaku and potential total cash infusions exceeding $200 million.
Revenue Expectations: Revenues for Q1 2025 were zero, compared to $4.9 million in Q1 2024, with no current revenue sources.
Operating Expenses: R&D expenses for Q1 2025 were approximately $16.2 million, and G&A expenses were approximately $3.1 million.
Net Loss: Net loss for Q1 2025 was approximately $24.4 million, compared to a net loss of approximately $9.8 million in Q1 2024.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Cash Position: As of March 31, 2025, Capricor Therapeutics had a cash balance of approximately $145 million.
Potential Milestone Payment: If FDA approval is received, Capricor is slated to receive an $80 million milestone payment from Nippon Shinyaku.
Non-Dilutive Cash Infusions: Potential total cash infusions could exceed $200 million, including the Priority Review Voucher.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Have you guys had your site inspection yet in San Diego? And if not, can you tell us when that’s scheduled for?
A:We haven’t had our pre-licensing inspection. It’s coming up this quarter within the next few weeks.
Q:Can you walk us through maybe what you consider to be key features and anything along the lines in terms of particular prep for the adcom?
A:We are actively working on adcom prep and have already had two mock adcoms, which we passed with flying colors.
Q:Just wondering if we could also maybe read into that, that you may be considering an alternative mechanism for launching in Europe, perhaps on your own?
A:We are evaluating the opportunity in Europe and remain in active negotiations with Nippon Shinyaku.
Q:If you could just share to the extent you can kind of how they’re set up here in terms of their footprint for marketing, deramiocel presenting approval?
A:They have built a sales and marketing distribution team for Viltepso, with 125 FTEs focusing on deramiocel.
Q:What are the biggest key drivers that these physicians say is that proof?
A:The statistical significance of the data is a key driver, particularly using cardiac MRI as an objective measure.
Q:Will you have any four-year data to share at that point with the agency?
A:We plan on presenting the four-year data at the PPMG meeting in June.
Q:Has there been a lot of changes within the FDA personnel that you’ve been speaking with?
A:We see the FDA stabilizing, and most of the reviewers we’ve worked with are still engaged.
Q:What’s the plan if the FDA issues a CRL for efficacy in August?
A:We would submit the data for the HOPE-3 trial for skeletal muscle dysfunction.
Q:What specific feedback has the FDA given you about LVF as a surrogate endpoint?
A:FDA has stated they’re not looking at ejection fraction as a surrogate endpoint in this situation.
Q:Would you plan to sell the PRV voucher right away?
A:Our current plan is to sell it to strengthen our balance sheet.
Q:Have the participants indicated the type of profile that would make deramiocel best in indication?
A:We are looking for the presence of LGE or cardiac dysfunction measured by ejection fraction.
Q:Can you provide some color on the progress achieved with the Japanese regulators?
A:We’re actively working with Japanese regulators and have upcoming meetings.
Q:Can you speak to the adcom’s committee composition and expertise?
A:The components of the adcom are available online, but we don’t have a date yet.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer regarding the specific composition of the adcom committee and the exact timeline for the Japanese regulatory progress.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Action deramiocel
Advisory Committee
BLA application
BLA approval
CDCs Mechanism
Capricor deramiocel
Capricor medicine
DMD cardiomyopathy
DMD therapeutic
Diego GMP
Dr
HOPE study
Medical
Nippon Shinyaku
Research
adcom
approval deramiocel
boy
chance
class therapy
concern
dataset
delivery
drug
dystrophinopathy
exosome
exosomes
infusion
matter
men life
mutation
need
negotiation
physician
prescribing
size
therapy market
update program
world
CAPR Transcript
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q1 2025 Earnings Call Transcript
Unknown5-14
The earnings call reveals significant financial challenges, including a net loss increase and zero revenue for Q1 2025, raising concerns about financial sustainability. Despite a strong cash position and potential milestone payments, extended negotiations and increased expenses further contribute to a negative outlook. The Q&A session highlighted uncertainties in regulatory progress and market entry delays. Overall, the financial struggles and uncertainties outweigh the potential positive impacts, leading to a negative sentiment rating.
Capricor Therapeutics, Inc. (CAPR) Q3 2024 Earnings Call Transcript
Neutral11-14
The earnings call summary presents mixed signals. The financial performance shows a significant revenue decline and increased losses, which is concerning. However, the strong cash position and potential milestone payments from a European agreement are positive. The Q&A section highlights readiness for market launch and manufacturing capabilities, but there are uncertainties in trial designs and management responses. The public offering and cash position are positive, but the revenue decline and increased expenses dampen the overall sentiment, leading to a neutral prediction with potential for positive movement if milestones are achieved.
Capricor Therapeutics, Inc. (CAPR) Q2 2024 Earnings Call Transcript
Neutral8-9
Capricor Therapeutics, Inc. (CAPR) Q1 2024 Earnings Call Transcript
Positive5-14
The earnings call highlights significant progress in product development, strategic partnerships, and financial performance. Positive interim results in the Phase III trial, increased revenue, and reduced net loss are notable. The Q&A reveals confidence in regulatory strategies and strong safety profiles, despite some uncertainties. The potential for milestone payments and global expansion, along with a strong cash position, supports a positive outlook. However, increased R&D expenses and lack of specific guidance on milestone triggers and partnerships temper enthusiasm slightly. Overall, the stock is likely to see a positive movement in the short term.
CAPR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
